Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Urothelial Cancer 1Triple Negative Breast Neoplasms 1Lung Neoplasms 1Infiltrating Bladder Urothelial Carcinoma 1Colonic Neoplasms 1

Interventions

pembrolizumab 1Radiation Dose Hypofractionation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Urothelial Cancer × Radiation Dose Hypofractionation × Clear all
NCT02880345 2019-04-23

RADVAXâ„¢: A Trial of Combined Pembrolizumab and Hypofractionated Radiation in Patients With Advanced Urothelial Cancer Who Have Progressed on Anti-PD-1/PD-L1 Monotherapy

Abramson Cancer Center at Penn Medicine

Phase 1 Withdrawn
Genitourinary

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡